Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe president of Terre Haute Economic Development Corp. wants to look deeper into Pfizer Inc.’s troubles with its new inhaled insulin before
Steve Witt told the County Council it would be “good business” to learn more before making the final sale of the bonds, which would be paid back with taxes by from the New York-based giant, according to The Tribune-Star of
Pfizer hired nearly 400 full-time workers last year to build inventories in anticipation of launching the powder, called Exubera. The new workers doubled employment at the plant south of
But two weeks ago the company laid off temporary workers and stopped Sunday production.
Pfizer plans to relaunch Exubera in April after physicians greeted the rollout last fall with skepticism.
Quoting industry sources, the newspaper said lackluster demand has resulted in Pfizer’s accumulating nearly $800 million in Exubera inventories. By the end of the year, the projected $1.5 billion of inventory would supply demand for three years.
Eli Lilly and Co. CEO
“So far they haven’t done very well,” Taurel said.
Please enable JavaScript to view this content.